Compare · AZN vs BRNS
AZN vs BRNS
Side-by-side comparison of AstraZeneca PLC (AZN) and Barinthus Biotherapeutics plc (BRNS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and BRNS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 8549.6x BRNS ($30.2M).
- Over the past year, AZN is up 97.3% and BRNS is down 44.9% - AZN leads by 142.2 points.
- AZN has hit the wire 14 times in the past 4 weeks while BRNS has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 0 for BRNS).
- Company
- AstraZeneca PLC
- Barinthus Biotherapeutics plc
- Price
- $165.42-0.74%
- $0.76+6.03%
- Market cap
- $258.47B
- $30.2M
- 1M return
- -0.43%
- +27.17%
- 1Y return
- +97.28%
- -44.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest BRNS
- SEC Form 15-12G filed by Barinthus Biotherapeutics plc
- SEC Form EFFECT filed by Barinthus Biotherapeutics plc
- Amendment: Former 10% owner Oxford Science Enterprises Plc closing all direct ownership in the company (SEC Form 4)
- SEC Form 25 filed by Barinthus Biotherapeutics plc
- Director Scheeren Joseph returned 23,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Phillips Anne M. returned 3,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wright Robin returned 48,256 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Morgon Pierre A. returned 10,506 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Hammacher Alex returned 3,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Hooftman Leon was granted 361,530 units of Ordinary Shares and returned 361,530 units of Ordinary Shares to the company (SEC Form 4)